Select Location
What is your delivery location?
We need your delivery location to continue browsing
Select Location
We need your delivery location to continue browsing
Aprazer Healthcare Pvt Ltd
2 x14
Axitinib
Keep in cold place
Delivering To:
Overview
Inlybest 1mg Tablet is used for the treatment of kidney cancer. Inlybest 1mg tablet contains Axitinib as an active substance, and it is indicated for the treatment of renal cell carcinoma (a type of cancer that begins in the kidney). This anticancer formulation belongs to a group of medications known as tyrosine kinase inhibitors. Inlybest 1mg tablet is available in tablet form and works by blocking the action of an abnormal protein.
Kidney Cancer
Kidney cancer
Mild or major side effects may occur during treatment with Inlybest 1mg tablets. If side effects last longer than usual, inform your general practitioner as soon as possible.
Stomach pain
Heartburn
Headache
Dizziness
Rash
Itching
Dry skin
Pale skin
Fast heartbeat
Hair loss
Ringing in the ears
Thirst
Hemorrhoids
A wound or cut that will not heal
Diarrhea
Take the Inlybest 1mg tablet as prescribed by your health professional. Ensure you take this cancer-fighting formulation in the same amount as directed by your physician. In case of an overdose, the patient is advised to consult a general practitioner as soon as possible if any unusual symptoms occur. Inlybest 1mg tablet should be swallowed as a whole. Let your doctor know if you have liver, thyroid, kidney disease, etc, or are on some other medications. Inlybest tablet is not recommended for pregnant and breastfeeding women.
Inlybest 1mg tablet helps prevent the progression of cancer by inhibiting angiogenesis and blocking tumor growth. It selectively blocks the tyrosine kinase receptors VEGFR-1 (vascular endothelial growth factor receptor), VEGFR-2, and VEGFR-3. The formulation is mainly eliminated in the feces (about 41%) with nearly 12% of the original dose as unchanged axitinib. There is also 23% eliminated in the urine, most of which are metabolites.
Alcohol
unsafe
It is advisable not to consume alcohol while taking the Inlybest 1mg tablet.
Pregnancy
consult your doctor
Do not take the Inlybest 1mg tablet without consulting the doctor, in case of pregnancy. Inlybest 1mg tablet is considered not safe to use in case of pregnancy as it may harm the developing baby, according to research evidence.
Breast Feeding
consult your doctor
Without a doctor's consultation, do not take this medicine if you're breastfeeding. Inlybest 1mg tablet may cause toxicity to the developing baby as it may be transferred through the milk of the mother, so it's not considered safe to use Inlybest 1mg tablet during breastfeeding.
Driving
danger
It is advisable not to drive or operate heavy machinery, as one of the side effects of the medicine. Inlybest 1mg tablet can make you feel sleepy, affect your vision, and reduce alertness. It is advised not to drive if these symptoms exist while taking the Inlybest 1mg tablet.
Kidney
caution
Do not take the Inlybest tablet without a doctor's consultation in case of kidney problems. Patients with severe kidney disease should use Inlybest 1mg tablet with caution, and the patient may require an adjustment in dose as recommended by the doctor. A Regular kidney test should be done to monitor the side effects of Inlybest 1mg tablet on the kidneys.
Liver
caution
Share your medical history with the doctor in case of liver disease before taking this medicine. Patients with severe liver disease should use Inlybest 1mg tablet with caution, and the patient may require an adjustment in dose as recommended by the doctor. A Regular liver test should be done to monitor the side effects of Inlybest 1mg tablet on the kidneys.
If you miss a scheduled dose of Inlybest-1 tablet, contact your medical practitioner immediately to know the ways of coping with the missed or skipped dose.
Inlybest-1 contains Axitinib as an active substance and it is indicated for the treatment of renal cell carcinoma (a type of cancer that begins in the kidney). It helps in decreasing the spread of cancerous cells.
Common side effects of Inlybest-1 tablet are fever, chills, nausea, diarrhea, skin rash, allergy, headache, etc.
If you miss a scheduled dose of Inlybest-1 tablet, contact your medical practitioner immediately to know the ways of coping with the missed or skipped dose.
Inlybest-1 (Axitinib) tablets are not recommended for use in pregnant women because they may affect the unborn baby.
Administer Inlybest-1 tablets as prescribed by your general practitioner.
You should reduce or stop taking Inlybest 1mg tablets in case you experience severe side effects after taking the medicine. However, your doctor will decide the duration and amount of Inlybest 1mg tablets as treatment varies from individual to individual.
Your doctor may advise you to undergo certain medical tests, such as liver or pancreatic, blood pressure, kidney, urine tests, complete blood tests, and other necessary tests, before starting Inlybest 1mg tablets. Breastfeeding and pregnant women should provide attention before taking Inlybest 1mg tablets.
In case you miss a dose, take it as soon as you remember. Do not take a double dose to make up for the missed one. Only the best 1mg tablet should be taken on time, and you should continue with your regular dose.
The benefits of Inlybest 1mg tablet may take months or weeks to become noticeable. You should not discontinue the medicine without consulting your doctor.
A balanced diet is advised while taking Inlybest 1mg tablet. You should drink plenty of water and avoid consuming excessive amounts of sugar or salty food. Intake of alcohol should be avoided.
1. Gross-Goupil M, François L, Quivy A, Ravaud A. (2023). Axitinib: a review of its safety and efficacy in the treatment of adults with advanced renal cell carcinoma. Clin Med Insights Oncol. 29(7):269-77.
2. Keating GM. (2023). Axitinib: a review in advanced renal cell carcinoma. Drugs. 75(16):1903-13.
3. Mi-Hyang Jung, Yun-Seok Choi, Sang-Wook Yi, Sang Joon An, Jee-Jeon Yi, Sang-Hyun Ihm, So-Young Lee, Jong-Chan Youn, Woo-Baek Chung, Hae Ok Jung, Ho-Joong Youn. (2025). Socioeconomic status and cardiovascular mortality in over 170,000 cancer survivors, European Heart Journal - Quality of Care and Clinical Outcomes, 11(4), 406–414.
4. Oldani M, Cantone MC, Gaudenzi G, Carra S, Dicitore A, Saronni D, Borghi MO, Lombardi A, Caraglia M, Persani L, Vitale G. (2024). Exploring the multifaceted antitumor activity of axitinib in lung carcinoids. Front Endocrinol (Lausanne).
5. Shin SJ, Lee JL, Kwon TG, Shim BY, Chung HS, Kim SH, Park SH.(2025). Real-World Study Evaluating Safety and Effectiveness of Axitinib in Korean Patients with Renal Cell Carcinoma after Failure of One Prior Systemic Therapy. Cancer Res Treat. 55(2):643-651.
6. Tzogani K, Skibeli V, Westgaard I, Dalhus M, Thoresen H, Slot KB, Damkier P, Hofland K, Borregaard J, Ersbøll J, Salmonson T, Pieters R, Sylvester R, Mickisch G, Bergh J, Pignatti F. (2024). The European Medicines Agency approval of axitinib (Inlyta) for the treatment of advanced renal cell carcinoma after failure of prior treatment with sunitinib or a cytokine: summary of the scientific assessment of the committee for medicinal products for human use. Oncologist. ;20(2):196-201.
Aprazer Healthcare Pvt Ltd
Written By
Venika Choudhary
Medical Content Writer @ Magicine Pharma
I hold an M.Sc. in Microbiology and have a strong academic foundation in microbial sciences and applied biotechnology. I began my career with extensive hands-on research at CSIR laboratories, focusing on fungal enzyme production, studying fungal diversity in various ecosystems, and developing bio-pesticides as sustainable alternatives to chemical pesticides. This work deepened my understanding of fungal biology, bioactive compounds, and their pharmaceutical and agricultural applications. Transitioning from research, I now work as a medical content writer, where I combine my scientific expertise with a passion for clear and reliable healthcare communication. I apply my research background to create patient-friendly, compliant content for pharmaceutical companies and healthcare platforms, ensuring science is both trustworthy and accessible. Specializing in clear, accurate, and engaging content, I help patients make informed decisions and support pharmaceutical companies in delivering trusted information. Whether writing product descriptions, crafting disease awareness articles, or composing drug information leaflets, I consistently meet regulatory standards and address audience needs, making my content an asset for healthcare brands.
Reviewed By
Dr. Aditya Sarin - MBBS, MD, DrNB - Consultant Medical Oncology
Dr. Aditya Sarin, MBBS, MD, DrNB, is a highly qualified medical oncologist with profound research and clinical expertise, currently working at Sir Ganga Ram Hospital, New Delhi. He is also a member of the European Society of Medical Oncology (ESMO), a non-profit European organization dedicated to eradicating cancer by promoting comprehensive cancer care and advancing medical oncology. He has been honored with several awards, including the International Cancer Foundation scholarship (ESMO congress, 2022) and Young Medical Oncologist of the Year (Times of India, 2024). He is well-known for his breakthrough in oncology. Dr. Sarin is passionate about converting complex health information into a concise and clear form that is understandable to everyone, aiming to create awareness and cancer care among people.